ERBB2 and breast carcinoma: CNS metastasis is a significant issue in breast cancer regardless of HER2 status, affecting between 5–15% of patients [34,35]; this incidence is even higher in autopsy analysis to up to 30% [36], and HER2 positivity is an independent risk factor [37,38].